Table 1 Number of people in the study with each immune-mediated disease, and percentage of females.
Exposure cohort (and ICD code1) | ORLS1 | ORLS2 | England |
|---|---|---|---|
| Â | Total (% female) | Total (% female) | Total (% female) |
Addison's disease (255.4) | 489 (64) | 624 (60) | 10,257 (60) |
Ankylosing spondylitis (720) | 976 (30) | 991 (29) | 2,2001 (29) |
Autoimmune haemolytic anaemia (283) | 421 (55) | 377 (59) | 7,854 (55) |
Chronic active hepatitis (571.4) | 431 (61) | 209 (71) | 4512 (70) |
Coeliac disease (579.0) | 1,722 (61) | 2,324 (66) | 48,239 (66) |
Dermatomyositis, polymyositis (710.3,710.4) | 328 (63) | 268 (70) | 6,002 (63) |
Diabetes mellitus under 30 (250) | 4,950 (47) | 4,410 (48) | 79,581 (48) |
Goodpasture's syndrome (446.2) | 76 (53) | 53 (43) | 999 (45) |
Hashimoto's thyroiditis (245) | 524 (87) | 384 (90) | 8,573 (88) |
Idiopathic thrombocytopenia purpura (287.3) | 779 (54) | 1,221 (57) | 25,984 (55) |
Multiple sclerosis (340) | 3,823 (66) | 4,106 (68) | 81,950 (68) |
Myasthenia gravis (358) | 379 (63) | 420 (57) | 10,024 (51) |
Myxoedema (244) | 6,738 (82) | 23,456 (81) | 63,0354 (81) |
Pemphigus, pemphigoid (694.4,694.5) | 537 (57) | 492 (57) | 11,480 (57) |
Pernicious anaemia (281) | 4,131 (63) | 1,457 (70) | 47,092 (68) |
Polyarteritis nodosa (446) | 298 (42) | 84 (42) | 2,088 (43) |
Primary biliary cirrhosis (571.6) | 359 (77) | 367 (83) | 9,060 (85) |
Psoriasis (696.0,696.1,696.8,696.9) | 3,910 (52) | 3,365 (48) | 85,358 (48) |
Rheumatoid arthritis (714) | 14,231 (73) | 11,241 (72) | 268,005 (71) |
Scleroderma (710.1) | 363 (80) | 542 (85) | 11,643 (82) |
Sjogren's syndrome (710.2) | 165 (86) | 446 (89) | 12,680 (89) |
Systemic lupus erythematosus (710.0) | 594 (86) | 997 (87) | 23,544 (87) |
Thyrotoxicosis (242) | 5,503 (81) | 3,986 (89) | 91,913 (79) |